WORLD'S FIRST PERMANENT INJECTABLE IMPLANT,
Cellulora™ is developing a novel cellulose-based material for soft tissue repair. It’s designed to be an injectable, long-term filler with biocompatibility matching autologous tissue.
At Cellulora™, we are committed to redefining healthcare by developing safe, innovative biomaterials that make patients look and feel better.
There is a need in medicine for safer, more effective biomaterials for use in tissue reconstruction.
Current injectable implants and fillers are limited in their ability to immediately correct contour defects and in their longevity.
Cellulora's™ product pipeline combines natural plant-based ingredients and amazing chemistry to produce safe and effective long-term implants.
Cellulora’s™ patented technology is based on derivatives of the plant polysaccharide, cellulose, which are modified to achieve stable material properties that match native soft tissue. Cellulora's™ two-component cellulose-based filler thermally gels upon injection and, within minutes, forms a chemically crosslinked hydrogel.
Unlike other natural long-term fillers that are prone to breakdown due to the activity of enzymes present in the body, our cellulosic materials cannot be degraded naturally due to the lack of the cellulase enzyme in humans.
This creates a stable volumizing material that can maintain shape and functional properties over a long duration.
Properties such as viscosity and stiffness can be tuned for various applications and anatomical locations.
Although stable, Cellulora’s™ hydrogels can be selectively reversed by enzymatic treatment.
Selectively Reversible within 24 hours via Enzymatic Treatment
MADE FROM INEXPENSIVE, RENEWABLE MATERIAL
PROVIDES IMMEDIATE BULKING EFFECT
NON-DEGRADABLE, YET REVERSIBLE
MAINTAINS SHAPE AND STRUCTURAL STABILITY OVER LONG TIME PERIODS
Take a look at our 1-min Pitch Video from the 2023 MedTech Innovator $10,000 Best Video Competition!
MEET THE TEAM
Chief Executive Officer
An entrepreneur with extensive experience (30 years) in medical devices, diagnostics, and therapeutics, and a founder and leader.
STEVEN NICOLL, PH.D.
Chief Scientific Officer
Professor of Biomedical Engineering at the City College of New York.
B.S.E. in Bioengineering from the University of Pennsylvania
Ph.D. in Bioengineering from the Univ. of California, Berkeley and San Francisco
Post-Doc in Biomedical Engineering at Columbia University
PETER J. TAUB, MD, MS, FAACS, FAAP
System Chief, Division of Plastic and Reconstructive Surgery, Mount Sinai Hospital
Board Certified Cosmetic, Plastic & Reconstructive Surgeon, New York, NY
IN THE NEWS
October 9, 2023
Cellulora™ is featured at the AdvaMed MedTech Conference in Anaheim, CA in the MedTech Innovator Advanced Materials Showcase Panel.